In-Depth Examination Of 6 Analyst Recommendations For Alpine Immune Sciences
Portfolio Pulse from Benzinga Insights
Alpine Immune Sciences (NASDAQ:ALPN) received mixed analyst ratings with 1 bullish and 5 somewhat bullish over the past three months. The average 12-month price target increased to $28.5, up 45.41% from the previous $19.60, with a high estimate of $35.00 and a low of $22.00. Analysts from firms like Wedbush and Morgan Stanley have raised their price targets, reflecting positive sentiment towards ALPN's market position and financial health, despite its revenue growth trailing the Health Care sector average.
January 26, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alpine Immune Sciences has received mixed analyst ratings but an increased average price target of $28.5, suggesting a positive outlook. The company's financial health indicators such as revenue growth and ROE are strong, despite trailing the sector average in growth rate.
The increase in the average price target reflects a positive sentiment from analysts, which could lead to increased investor confidence and a potential short-term rise in ALPN's stock price. The financial health indicators such as solid revenue growth and impressive ROE support this positive outlook, although the revenue growth rate is lower than the sector average, which might temper the impact slightly.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100